Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fesoterodine
Drug ID BADD_D00891
Description Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
Indications and Usage For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
Marketing Status approved
ATC Code G04BD11
DrugBank ID DB06702
KEGG ID D07226
MeSH ID C526675
PubChem ID 6918558
TTD Drug ID D00BLL
NDC Product Code 47621-025; 50370-0047
UNII 621G617227
Synonyms fesoterodine | toviaz | fesoterodine fumarate
Chemical Information
Molecular Formula C26H37NO3
CAS Registry Number 286930-02-7
SMILES CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neurogenic bladder20.03.03.001; 17.10.01.0020.000496%Not Available
Nocturia20.02.03.0010.004366%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.001836%
Orthostatic hypotension24.06.03.004; 17.05.01.0200.000496%Not Available
Osteoarthritis15.01.04.0010.000744%Not Available
Palpitations02.11.04.0120.003523%
Pelvic pain07.01.06.012; 21.10.01.001; 20.02.03.007--
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.0160.000744%Not Available
Pollakiuria20.02.02.0070.008335%
Pre-existing condition improved08.01.03.0430.001687%Not Available
Productive cough22.02.03.0050.001687%
Prostatitis21.09.01.0010.000744%Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.0010.000744%
Renal disorder20.01.02.0020.000496%Not Available
Renal failure20.01.03.0050.001488%Not Available
Rheumatoid arthritis15.01.03.001; 10.04.06.0010.000496%Not Available
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.0060.006450%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.001935%Not Available
Stress19.06.02.0040.002530%Not Available
Swelling08.01.03.015--Not Available
Swelling face23.04.01.018; 10.01.05.018; 08.01.03.1000.001588%Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.0030.001588%Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.003076%
Tachycardia02.03.02.0070.002679%Not Available
Therapeutic response decreased08.06.01.0160.001836%Not Available
Therapeutic response unexpected08.06.01.0010.002778%Not Available
Thirst14.03.02.007; 08.01.09.0210.000992%Not Available
The 5th Page    First    Pre   5 6 7 8    Next   Last    Total 8 Pages